91669
document
[ Prevention of vascular complications following cerebral ischemia of arterial origin ; the ESPRIT trial : mild anticoagulant therapy , combination treatment with acetylsalicylic acid plus dipyridamole or treatment with acetylsalicylic acid alone ? ] . The European and Australian Stroke Prevention in Reversible Ischaemia Trial ( ESPRIT ) is a randomised clinical trial in which patients with cerebral ischaemia of arterial origin will be randomised between oral anticoagulation ( international normalized ratio ( INR ) : 2.0-3.0 ) , the combination of acetylsalicylic acid ( in any dose between 30 and 325 mg per day ) plus dipyridamole ( 400 mg daily ) and acetylsalicylic acid only ( in any dose between 30 and 325 mg per day ) . It is planned to enroll 4500 patients with a mean follow-up of three years . Primary outcome is the composite event of vascular death , stroke , myocardial infarction , or major bleeding complication ; outcome assessment will be blinded . ESPRIT is an international , multicentre study in which 60-80 hospitals in the Netherlands and other countries in Europe and Australia will participate .
91670
Intervention_Pharmacological
mild anticoagulant therapy
91671
Intervention_Pharmacological
acetylsalicylic acid
91672
Intervention_Pharmacological
dipyridamole
91673
Intervention_Pharmacological
acetylsalicylic acid
91674
Intervention_Pharmacological
oral anticoagulation
91675
Intervention_Pharmacological
acetylsalicylic acid
91676
Intervention_Pharmacological
dipyridamole
91677
Intervention_Pharmacological
acetylsalicylic acid
91678
Outcome_Adverse-effects
vascular complications
91679
Outcome_Mortality
composite event of vascular death ,
91680
Outcome_Physical
stroke
91681
Outcome_Mortality
,
91682
Outcome_Physical
myocardial infarction
91683
Outcome_Mortality
, or
91684
Outcome_Adverse-effects
major bleeding complication
91685
Outcome_Mortality
;